Skip to main content
. 2017 Apr 19;9(1):15–32. doi: 10.1007/s13238-017-0408-4

Figure 4.

Figure 4

A typical TMDD graph exhibiting the relationship between clearance or t1/2 and mAb dose. Anti-αv mAb was infused to cancer patients; clearance or terminal half-life (t1/2) was plotted against dose (0.1, 0.3, 1, 3, and 10 mg/kg). Adapted from Mullamitha et al., Clin Cancer Res. (2007)